EFFECTS OF CALCIUM ANTAGONIST, BENIDIPINE, ON THE PROGRESSION OF CHRONIC RENAL FAILURE IN THE ELDERLY: A 1-YEAR FOLLOW-UP

REFERENCES

• Kasiske B., Lakatua J., Ma J., Louis T. A meta-analysis of the effects of dietary protein restrictionon the rate of decline in renal function. Am. J. Kidney Dis. 1998; 31: 954–961
   PubMed Web of Science ®Google Scholar
• Remuzzi G., Ruggenenti P., Benicni A. Understanding the nature of renal disease progression. Kidney Int. 1997; 51: 2–15
   PubMed Web of Science ®Google Scholar
• National High Blood Pressure Eduction Program: National highblood pressure education program working group report on hypertension andchronic renal failure. Arch Intern Med 1991; 151: 1280–1287
   PubMedGoogle Scholar
• Silverman M., Bakris G. Treatment of renal failure and blood pressure. Cur Opin Nephrol Hypertens. 1997; 6: 237–242
   PubMed Web of Science ®Google Scholar
• Staessen J., Fagard R., Thijs L., Celis H., Arabidze G., Birkenhager W., Bulpitt C., de Leeuw P., Dollery C., Fletcher A., Forette F., Leonetti G., Nachev C., O'Brien E., Rosenfeld J., Rodicio J., Tuomilehto J., Zanchetti A. Randomized double-blind comparison of placebo and active treatmentfor older patients with isolated systolic hypertension. The Systolic Hypertensionin Europe (Syst-Eur) Trial Investigation. Lancet 1997; 350: 757–764
   PubMed Web of Science ®Google Scholar
• Kaplan N. Hypertension in the Elderly Program (SHEP) and Swedish Trialin Old Patients with Hypertension (STOP): the promises and the potential problems. Am. J. Hypertens. 1992; 5: 325–330
   PubMedGoogle Scholar
• Acone D., Cante D., Cillo F., Gioradano G., Gioradano C. Blood pressure and progression of renal failure in the elderly. Kidney Int. 1996; 55: S75–S77
   Google Scholar
• Kloke H., Branten A., Huysmans F., Wetzels J. Antihypertensive treatment of patients with proteinuric renaldiseases. Risks or benefits of calcium channel blockers?. Kidney Int. 1998; 53: 1559–1573
   PubMed Web of Science ®Google Scholar
• Zucchelli P., Zuccala A., Borghi M., Fusaroli M., Sasdelli M., Stallone C., Sanna G., Gaggi R. Long-term comparison between captopril and nifedipine in theprogression of renal insufficiency. Kidney Int. 1992; 42: 452–458
   PubMed Web of Science ®Google Scholar
• Hansson L., Zanchetti A., Carruthers S., Dahlof B., Elmfeldt D., Menard J., Rahn K. H., Wedel H., Westerling S. Effects of intensive blood pressure lowering and low-dose aspirinin patients with hypertension: principal results of the Hypertension OptimalTreatment (HOT) randomised trial HOT Study Group. Lancet 1998; 351: 1755–1762
   PubMed Web of Science ®Google Scholar
• Suzuki H., Saruta T. Benidipine. Cardiovasc. Drug Rev. 1989; 7: 25–58
   Google Scholar
• Dohi Y., Kojima M., Sato K. Benidipine improves endothelial function in renal resistancearteries of hypertensive rats. Hypertension 1996; 28: 58–63
   PubMed Web of Science ®Google Scholar
• Fujii Y., Suzuki H., Katsumata H., Nakajima S., Saruta T. Hormonal and renal responses to oral once-daily calcium entryblocker in normotensive and hypertensive persons. J. Cardiovasc Pharmacol 1988; 11: 438–443
   PubMed Web of Science ®Google Scholar
• Yoshida K., Kohzuki M., Yasujima M., Kanazawa M., Abe K. Effects of benidipine a calcium antagonist, on urinary kallikreinexcretion and renal impairment in experimental diabetes. J. Hypertens 1996; 14: 215–22
   PubMed Web of Science ®Google Scholar
• Maschio G., Alberti D., Janin G., Locatelli F., Mann J., Montolese M., Ponticelli C., Ritz E., Zucchelli P. Effect of the angiotensin converting-enzyme inhibitor benazeprilon the progression of chronic renal insufficiency. N Engl J. Med. 1996; 334: 939–945
   PubMed Web of Science ®Google Scholar
• Brazy P., Fitzwilliam J. Progressive renal disease: Role of race and antihypertensivemedications. Kidney Int. 1990; 37: 1113–1119
   PubMed Web of Science ®Google Scholar
• Iseki K., Iseki C., Ikemiya Y., Fukiyama K. Risk of developing endstage renal disease in a cohort of massscreening. Kidney Int. 1996; 49: 800–805
   PubMed Web of Science ®Google Scholar
• Klag M., Whelton P., Randall B., Neaton J., Brancati F., Ford C., Shulman N., Stamler J. Blood pressure and end-stage renal disease in men. N. Engl J. Med. 1996; 334: 13–18
   PubMed Web of Science ®Google Scholar
• Perry H., J P. M., Rossiter J., Fornoff R., Baty J., Smabilin M., Rutan G., Moskowitz D., Carmody S. Early predictors of 15 year end-stage renal disease in hypertensivepatients. Hypertension 1995; 25: 587–594
   PubMed Web of Science ®Google Scholar
• Walker W. Hypertension-related renal injury: a major contributor to end-stagerenal disease. Am. J. Kidney DIs 1993; 22: 164–173
   PubMed Web of Science ®Google Scholar
• The Modification of Diet in Renal Disease Study: design, methodsand results from the feasibility study. Am. J. Kidney Dis. 1992; 20: 18–33
   PubMed Web of Science ®Google Scholar
• Ruggenenti P., Perna A., Mosconi L., Pisoni R., Remuzzi G. Urinary protein excretion rate is the best independent predictorof ESRF in non-diabetic proteinuric chronic nephropathies. Kidney Int. 1998; 53: 1209–1216
   PubMed Web of Science ®Google Scholar
• Glynn R., Field T., Rosner B., Hebert P., Taylor J., Hennekens C. Evidence for a positive linear relation between blood pressureand mortality in elderly people. Lancet 1995; 345: 825–829
   PubMed Web of Science ®Google Scholar
• Anderson S., Meyer T., Rennke H., Brenner B. Mechanism underlying transition from acute glomerular injuryto glomerulosclerosis in rat model of nephrotic syndrome. J. Clin Invest. 1985; 82: 1757–1768
   Google Scholar
• Brunner H. ACE inhibitors in renal disease. Kidney Int. 1992; 42: 463–479
   PubMed Web of Science ®Google Scholar
• Giatras I., Lau J., Levey A. For the Angiotensin-Converting-Enzyme Inhibition and ProgressiveRenal Disease Study Group: Effect of angiotensin-converting-enzyme inhibitorson the progression of nondiabetic renal disease: A meta-analysis of randomizedtrials. Ann. Intern Med. 1997; 127: 337–345
   PubMed Web of Science ®Google Scholar
• Maschio G. Protecting the residual renal function: How do ACE inhibitorsand calcium antagonists compare?. Nephron 1994; 67: 257–262
   PubMed Web of Science ®Google Scholar
• Susic D., Frohlich E. Nephroprotective effect of antihypertensive drugs in essentialhypertension. J. Hypertens 1998; 16: 555–567
   PubMed Web of Science ®Google Scholar
• Ter P. Wee, De Micheli A., Epstein M. Effects of calcium antagonists on renal hemodynamics and progressionof nondiabetic chronic renal disease. Arch Intern Med. 1994; 154: 1185–1202
   PubMed Web of Science ®Google Scholar
• Bianchi S., Bigazzi R., Baldari G., Campese V. Long-term effects of enalapril and nicardipine on urinary albuminexcretion in patients with chronic renal insufficiency. A 1-year follow-up. Am. J. Nephrol 1991; 11: 131–137
   PubMed Web of Science ®Google Scholar
• Tuomilehto J., Rastenyte D., Birkenhager W., Thijs L., Antikainen R., Bulpitt C., Fletcher A., Forette F., Goldhaber A., Palatini P. S.C., Fagard R. For the Systolic Hypertension in Europe Trial: Effects of calcium-channelblockade in older patients with diabetes and systolic hypertension. N. Engl. J. Med. 1999; 340: 7677–7684
   Google Scholar
• USRDS 1998 Annual DATA REPORT. Am. J. Kidney Dis. 1998; 32(Suppl. 1)
   Google Scholar
• Lazarus J., Bourgoignie J., Buckalew V., Greene T., Levey A., Milas N., Paranandi L., Peterson J., Porush J., Rauch S., Souci J., Stollar C. For the Modification of Diet in Renal Disease Study Group: Achievementand safety of a low blood pressure goal in chronic renal disease. The Modificationof Diet in Renal Disease Study Group. Hypertension 1997; 29: 641–650
   PubMed Web of Science ®Google Scholar
• Burgess E. Conservative treatment to slow deterioration of renal function:Evidence-based recommendations. Kidney Int. 1999; 5(Suppl. 70)S17–S25
   Google Scholar
• De Leeuw P. Renal function in the elderly: results from the European workingparty on high blood pressure in the elderly trial. Am. J. Med. 1991; 90(suppl 3A)3A-45S-39S
   Google Scholar
• Saruta T., Suzuki H. Efficacy of manidipine in the treatment of hypertension withrenal impairment: a multicenter trial. Am. Heart J. 1993; 125: 630–634
   PubMed Web of Science ®Google Scholar
• Takenaka T., Suzuki H., Ikenaga H., Itaya Y., Yamakawa H., Sakamaki Y., Saruta T. Effects of calcium channel blocker, nicardipine, on pressure-natriuresisin Dahl salt-sensitive rats. Clin and Exper Hypertension 1994; 16: 77–88
   PubMed Web of Science ®Google Scholar